| Q89943881 | A New Risk Variant for Multiple Sclerosis at 11q23.3 Locus Is Associated with Expansion of CXCR5+ Circulating Regulatory T Cells |
| Q36267021 | A Stromal Cell Niche for Human and Mouse Type 3 Innate Lymphoid Cells. |
| Q26851559 | A role for Th17 cells in the regulation of tertiary lymphoid follicles |
| Q48325814 | Activated B Cells Participating in the Anti-Myelin Response Are Excluded from the Inflamed Central Nervous System in a Model of Autoimmunity that Allows for B Cell Recognition of Autoantigen |
| Q40530656 | Activated GL7+ B cells are maintained within the inflamed CNS in the absence of follicle formation during viral encephalomyelitis. |
| Q43881975 | Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine. |
| Q38975695 | Anti-CD20 monoclonal antibodies in multiple sclerosis |
| Q47603503 | Anti-CXCL13 antibody can inhibit the formation of gastric lymphoid follicles induced by Helicobacter infection |
| Q36667911 | Astrocyte-derived CXCL10 drives accumulation of antibody-secreting cells in the central nervous system during viral encephalomyelitis |
| Q36878427 | Astrocytes--friends or foes in multiple sclerosis? |
| Q93047673 | Autoimmune-Mediated Retinopathy in CXCR5-Deficient Mice as the Result of Age-Related Macular Degeneration Associated Proteins Accumulation |
| Q38653397 | Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology |
| Q26801386 | B Cells and Autoantibodies in Multiple Sclerosis |
| Q35613006 | B cell antigen presentation is sufficient to drive neuroinflammation in an animal model of multiple sclerosis |
| Q36220292 | B cell repertoire expansion occurs in meningeal ectopic lymphoid tissue. |
| Q35903957 | B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases |
| Q55512364 | B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis. |
| Q91236273 | B cells in autoimmune and neurodegenerative central nervous system diseases |
| Q36981274 | B-cells and humoral immunity in multiple sclerosis. Implications for therapy |
| Q24646563 | BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma |
| Q34012753 | BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis |
| Q37593590 | BAFF: a local and systemic target in autoimmune diseases |
| Q36260857 | Blockade of B-cell activating factor with TACI-IgG effectively reduced Th1 and Th17 cells but not memory T cells in experimental allergic encephalomyelitis mice |
| Q35185219 | CCR2-dependent dendritic cell accumulation in the central nervous system during early effector experimental autoimmune encephalomyelitis is essential for effector T cell restimulation in situ and disease progression |
| Q37652166 | CCR7 deficient inflammatory Dendritic Cells are retained in the Central Nervous System |
| Q53015646 | CNS myeloid DCs presenting endogenous myelin peptides 'preferentially' polarize CD4+ T(H)-17 cells in relapsing EAE. |
| Q46275246 | CNS viral infection diverts homing of antibody-secreting cells from lymphoid organs to the CNS. |
| Q37299504 | CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice |
| Q36515088 | CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. |
| Q35869068 | CXCL13 expression in Chlamydia trachomatis infection of the female reproductive tract |
| Q36161486 | CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation |
| Q36788638 | CXCL13 promotes isotype-switched B cell accumulation to the central nervous system during viral encephalomyelitis |
| Q37314840 | CXCL13/CXCR5 enhances sodium channel Nav1.8 current density via p38 MAP kinase in primary sensory neurons following inflammatory pain |
| Q92712543 | Central Nervous System Inflammatory Aggregates in the Theiler's Virus Model of Progressive Multiple Sclerosis |
| Q21144285 | Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis |
| Q34504952 | Cerebrospinal fluid IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active intrathecal inflammation |
| Q35850791 | Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome |
| Q57083643 | Chapter 7 A Neuropathologist's Diary |
| Q28585797 | Chemokine CXCL13 is essential for lymph node initiation and is induced by retinoic acid and neuronal stimulation |
| Q37084908 | Chemokine CXCL13 mediates orofacial neuropathic pain via CXCR5/ERK pathway in the trigeminal ganglion of mice |
| Q39227824 | Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain. |
| Q92669017 | Chronic inflammation in multiple sclerosis - seeing what was always there |
| Q47935420 | Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients. |
| Q35529255 | Cognitive impairment in multiple sclerosis: clinical, radiologic and pathologic insights. |
| Q35929137 | Complexity of the microglial activation pathways that drive innate host responses during lethal alphavirus encephalitis in mice |
| Q36266751 | Cytomegalovirus latency promotes cardiac lymphoid neogenesis and accelerated allograft rejection in CMV naïve recipients |
| Q52319805 | Daclizumab Therapy for Multiple Sclerosis. |
| Q27022517 | Daclizumab therapy for multiple sclerosis |
| Q36535669 | Death ligands and autoimmune demyelination |
| Q42036256 | Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice |
| Q47357498 | Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. |
| Q22252805 | Disease Biomarkers in Multiple Sclerosis |
| Q37328280 | Disease-modifying agents for multiple sclerosis: recent advances and future prospects |
| Q38121632 | Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies. |
| Q40557011 | Early IL-1 Signaling Promotes iBALT Induction after Influenza Virus Infection |
| Q37075235 | Ectopic lymphoid tissues and local immunity |
| Q84580976 | Elevated production of B cell chemokine CXCL13 is correlated with systemic lupus erythematosus disease activity |
| Q37778622 | Emerging concepts in autoimmune encephalomyelitis beyond the CD4/TH1 paradigm |
| Q26770818 | Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis |
| Q38361889 | Exploring the origins of grey matter damage in multiple sclerosis. |
| Q34742821 | Factors supporting intrathecal humoral responses following viral encephalomyelitis. |
| Q26795577 | Follicular Helper CD4+ T Cells in Human Neuroautoimmune Diseases and Their Animal Models |
| Q36250237 | Follicular dendritic cells in health and disease |
| Q36919822 | Glial cell activation, recruitment, and survival of B-lineage cells following MCMV brain infection |
| Q35223938 | High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis. |
| Q39851981 | Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. |
| Q34251673 | Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. |
| Q35916972 | In situ activation of antigen-specific CD8+ T cells in the presence of antigen in organotypic brain slices |
| Q37655201 | Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. |
| Q34586903 | Inducible bronchus-associated lymphoid tissue (iBALT) in patients with pulmonary complications of rheumatoid arthritis. |
| Q92339537 | Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis |
| Q37370568 | Inflammation induces neuro-lymphatic protein expression in multiple sclerosis brain neurovasculature |
| Q36884649 | Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. |
| Q26851694 | Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments |
| Q38084075 | Intrathecal humoral immunity to encephalitic RNA viruses. |
| Q64066412 | Longitudinally persistent cerebrospinal fluid B cells can resist treatment in multiple sclerosis |
| Q37186200 | Lymphoid chemokines in chronic neuroinflammation |
| Q34020894 | Lymphoid chemokines in the CNS. |
| Q36405080 | Lymphoid neogenesis in chronic inflammatory diseases. |
| Q36426808 | Lymphoid organ development: from ontogeny to neogenesis |
| Q26770380 | Meningeal Tertiary Lymphoid Tissues and Multiple Sclerosis: A Gathering Place for Diverse Types of Immune Cells during CNS Autoimmunity |
| Q37909028 | Modulation of dendritic cell function by PGE2 and DHA: a framework for understanding the role of dendritic cells in neuroinflammation |
| Q58105796 | Myeloid-derived suppressor cells control B cell accumulation in the central nervous system during autoimmunity |
| Q42370355 | Narcolepsy and influenza vaccination-the inappropriate awakening of immunity |
| Q24645165 | Neuroprotection and remyelination after autoimmune demyelination in mice that inducibly overexpress CXCL1 |
| Q36991434 | New insights into adaptive immunity in chronic neuroinflammation |
| Q36735031 | Novel role for SLPI in MOG-induced EAE revealed by spinal cord expression analysis |
| Q36596483 | Pathogenesis of prion diseases: current status and future outlook |
| Q33673190 | Permissive environment for B‐cell maturation in myositis muscle in the absence of B‐cell follicles |
| Q42801736 | Prevention of murine experimental autoimmune encephalomyelitis by in vivo expression of a novel recombinant immunotoxin DT390-RANTES. |
| Q34059107 | Progression from IgD+ IgM+ to isotype-switched B cells is site specific during coronavirus-induced encephalomyelitis. |
| Q36076923 | RORγt Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis |
| Q37285430 | Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. |
| Q33772300 | Regulated Production of CXCL13 within the Central Nervous System |
| Q47157742 | Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy |
| Q37037819 | Role of B:T cell ratio in suppression of clinical signs: a model for silent MS |
| Q57825775 | Role of CXCL13 in the formation of the meningeal tertiary lymphoid organ in multiple sclerosis |
| Q37765477 | Role of lymphotoxin and homeostatic chemokines in the development and function of local lymphoid tissues in the respiratory tract. |
| Q43266829 | Serum levels of CXCL13 are elevated in active multiple sclerosis |
| Q47110972 | Spoiling for a Fight: B Lymphocytes As Initiator and Effector Populations within Tertiary Lymphoid Organs in Autoimmunity and Transplantation. |
| Q28068106 | Stromal Fibroblasts in Tertiary Lymphoid Structures: A Novel Target in Chronic Inflammation |
| Q37754572 | T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies |
| Q36551188 | Targeting CXCL13 During Neuroinflammation |
| Q28071379 | Tertiary Lymphoid Organs in Central Nervous System Autoimmunity |
| Q58746430 | Tertiary Lymphoid Structures: Autoimmunity Goes Local |
| Q43887998 | Tertiary lymphoid organ development coincides with determinant spreading of the myelin-specific T cell response |
| Q38012568 | Tertiary lymphoid organs in infection and autoimmunity |
| Q39201665 | Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective? |
| Q36474316 | The B cell response in multiple sclerosis |
| Q24796930 | The current status of targeting BAFF/BLyS for autoimmune diseases |
| Q38186206 | The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. |
| Q102379386 | The frequency of follicular T helper cells differs in acute and chronic neuroinflammation |
| Q35104199 | The lymphoid chemokine, CXCL13, is dispensable for the initial recruitment of B cells to the acutely inflamed central nervous system |
| Q37818131 | The potential role of B cell-targeted therapies in multiple sclerosis |
| Q92302527 | The role of B cells in multiple sclerosis: Current and future therapies |
| Q36079860 | The role of BAFF in immune function and implications for autoimmunity |
| Q39090618 | The role of peripheral immune cells in the CNS in steady state and disease |
| Q26851476 | The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects |
| Q37737305 | Treating multiple sclerosis with monoclonal antibodies: a 2010 update. |
| Q34083294 | Type-I interferons suppress microglial production of the lymphoid chemokine, CXCL13. |
| Q46927946 | Unaltered levels of transplant arteriosclerosis in the absence of the B cell homing chemokine receptor CXCR5. |
| Q35463552 | Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets |
| Q51958899 | [Targeting B cells in multiple sclerosis. Current concepts and strategies]. |
| Q80434989 | [Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis] |